|
|
Article: Enzo Biochem Executive Says Oral Immune Regulation Platform Shows "Therapeutic Promise".(Clinical report)
- Article from:
- Business Wire
- Article date:
- November 4, 2009
CopyrightCOPYRIGHT 2009 Business Wire. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Speaking at Bio-Europe 2009 Conference in Austria, Research and Clinical Studies for Treatment of Crohn's Disease and Uveitis Cited
VIENNA -- Enzo Biochem, Inc. (NYSE:ENZ) today reported on the Company's therapeutic platforms utilizing oral immune regulation for immune mediated diseases at the Bio-Europe 2009 15th Annual International Conference here calling it a "bright area of therapeutic promise."
"Our therapeutics subsidiary has long viewed oral immune regulation as an exciting and promising platform and one that we continue to pursue through studies involving treatment candidates for unmet medical needs," the meeting was told by David Goldberg, ...